High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2016-02

AUTHORS

Marc C. Chamberlain

ABSTRACT

Treatment of recurrent primary CNS lymphoma (PCNSL) though not standardized most often utilizes whole brain radiotherapy, re-challenge with high-dose methotrexate, or administration of an alkylating chemotherapy. High-dose cytarabine (HD-araC) has been advocated as an active agent in PCNSL but limited information exists regarding single agent activity in the recurrent setting. A retrospective review of 14 patients (10 males, 4 females: median age 60 years) with recurrent PCNSL treated at second recurrence with single agent HD-araC. HD-araC was administered at 3gm/m(2) over a 3-h infusion every 12 h for a total of 4 doses (defined as a cycle of therapy). GM-CSF was administered at conclusion of HD-araC. Patients were clinically and radiographically evaluated every 4-weeks. Common toxicity criteria Grade 3 or 4 toxicity included thrombocytopenia (11 patients; 79%), anemia (10; 71%), fatigue (8; 57%), mucositis (8; 57%), neutropenia (8; 57%) and neutropenic fever (5; 36%). No patient discontinued therapy due to toxicity nor were there any treatment-related deaths. Best response to HD-araC was stable disease in 6 patients (43%), partial response in 5 (36%) and progressive disease in 3 (21%). Median progression free survival 3 months (range 2-5 months; 95% CI 2-4 months) and progression free survival was 0% at 6-months. Median survival after onset of HD-araC was 12 months (range 3-18+ months; 95% CI 3-15 months). Single agent HD-araC has limited activity in recurrent PCNSL and is associated with significant toxicity in this small retrospective study. More... »

PAGES

545-550

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11060-015-1994-8

DOI

http://dx.doi.org/10.1007/s11060-015-1994-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1003110938

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26563190


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Central Nervous System Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytarabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma, Non-Hodgkin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Salvage Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Department of Neurology and Neurological Surgery, Fred Hutchinson Cancer Research Institute, Seattle Cancer Care Alliance, University of Washington, 825 Eastlake Avenue East, POB 19023, Mailstop: G-4940, 98109-1023, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chamberlain", 
        "givenName": "Marc C.", 
        "id": "sg:person.01326261166.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326261166.36"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1093/neuonc/noq011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000678444"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6603660", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003449325", 
          "https://doi.org/10.1038/sj.bjc.6603660"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-0625", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005245142"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2013-06-453084", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005748974"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjh.12938", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005955639"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.26709", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012698413"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.01.161", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017320169"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-014-1370-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019739839", 
          "https://doi.org/10.1007/s11060-014-1370-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(09)61416-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031922698"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(10)70229-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034898942"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdt385", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039599713"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/pl00022772", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039758880", 
          "https://doi.org/10.1007/pl00022772"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.46.9957", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041546845"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdl070", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041563711"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-014-1411-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046834783", 
          "https://doi.org/10.1007/s11060-014-1411-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.50.4910", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048451486"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cpt1971126944", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051202875"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.0000000000000314", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064352101"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.0000000000000314", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064352101"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.0000000000000314", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064352101"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.54.8.1707", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064378617"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.3.742", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074750681"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1992.10.4.635", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1076951232"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1990.8.7.1277", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078716995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081349247", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1983.1.9.546", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1081839026"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-02", 
    "datePublishedReg": "2016-02-01", 
    "description": "Treatment of recurrent primary CNS lymphoma (PCNSL) though not standardized most often utilizes whole brain radiotherapy, re-challenge with high-dose methotrexate, or administration of an alkylating chemotherapy. High-dose cytarabine (HD-araC) has been advocated as an active agent in PCNSL but limited information exists regarding single agent activity in the recurrent setting. A retrospective review of 14 patients (10 males, 4 females: median age 60 years) with recurrent PCNSL treated at second recurrence with single agent HD-araC. HD-araC was administered at 3gm/m(2) over a 3-h infusion every 12 h for a total of 4 doses (defined as a cycle of therapy). GM-CSF was administered at conclusion of HD-araC. Patients were clinically and radiographically evaluated every 4-weeks. Common toxicity criteria Grade 3 or 4 toxicity included thrombocytopenia (11 patients; 79%), anemia (10; 71%), fatigue (8; 57%), mucositis (8; 57%), neutropenia (8; 57%) and neutropenic fever (5; 36%). No patient discontinued therapy due to toxicity nor were there any treatment-related deaths. Best response to HD-araC was stable disease in 6 patients (43%), partial response in 5 (36%) and progressive disease in 3 (21%). Median progression free survival 3 months (range 2-5 months; 95% CI 2-4 months) and progression free survival was 0% at 6-months. Median survival after onset of HD-araC was 12 months (range 3-18+ months; 95% CI 3-15 months). Single agent HD-araC has limited activity in recurrent PCNSL and is associated with significant toxicity in this small retrospective study.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s11060-015-1994-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "126"
      }
    ], 
    "name": "High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma", 
    "pagination": "545-550", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "0ed19811fb47587d939f1c6c5980bd6cbe7b69f38a74e31acfa99fee18822a6d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26563190"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309335"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11060-015-1994-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1003110938"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11060-015-1994-8", 
      "https://app.dimensions.ai/details/publication/pub.1003110938"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T15:55", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8664_00000530.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs11060-015-1994-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11060-015-1994-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11060-015-1994-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11060-015-1994-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11060-015-1994-8'


 

This table displays all metadata directly associated to this object as RDF triples.

207 TRIPLES      21 PREDICATES      69 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11060-015-1994-8 schema:about N0ad20b069bd94de5998505aee7ddf47a
2 N1cbc259369f040ae9877d9f9ff64da53
3 N327219ba2a5c479badfb5fba207608cb
4 N5176a00f7f2f40458546e9995a6329d7
5 N56352abda9744ea88d19169ec1a9bea8
6 N6218585c02814b2bb857d0fa7897768c
7 N8bc4bdadd0ba418ab8525a1e922310a2
8 Na7cafcb577de4c3ca733e5d114da020d
9 Nc6fa1d807f574c67a852e29c043b1288
10 Nca716da208764c1080e27edd1e6a26f4
11 Ne27e6d9004ee4ffb82911317db289285
12 Ne5c36423e7704946b4ff879e5ff41c07
13 Nebed6514c9a644d4b6b99b488e68d116
14 Necfbf4ab8f154f9ba94e5d1d0a6677bc
15 Ned233d1aa84440cc83ab5de563814e3f
16 Nfebee87f90be48e39a2c3a7e23c73815
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author N9df2b402b3e04fb8b10c5e74b694fd97
20 schema:citation sg:pub.10.1007/pl00022772
21 sg:pub.10.1007/s11060-014-1370-0
22 sg:pub.10.1007/s11060-014-1411-8
23 sg:pub.10.1038/sj.bjc.6603660
24 https://app.dimensions.ai/details/publication/pub.1081349247
25 https://doi.org/10.1002/cncr.26709
26 https://doi.org/10.1002/cpt1971126944
27 https://doi.org/10.1016/s0140-6736(09)61416-1
28 https://doi.org/10.1016/s1470-2045(10)70229-1
29 https://doi.org/10.1093/annonc/mdl070
30 https://doi.org/10.1093/annonc/mdt385
31 https://doi.org/10.1093/neuonc/noq011
32 https://doi.org/10.1111/bjh.12938
33 https://doi.org/10.1158/1078-0432.ccr-11-0625
34 https://doi.org/10.1182/blood-2013-06-453084
35 https://doi.org/10.1200/jco.1983.1.9.546
36 https://doi.org/10.1200/jco.1990.8.7.1277
37 https://doi.org/10.1200/jco.1992.10.4.635
38 https://doi.org/10.1200/jco.2001.19.3.742
39 https://doi.org/10.1200/jco.2005.01.161
40 https://doi.org/10.1200/jco.2012.46.9957
41 https://doi.org/10.1200/jco.2013.50.4910
42 https://doi.org/10.1212/wnl.0000000000000314
43 https://doi.org/10.1212/wnl.54.8.1707
44 schema:datePublished 2016-02
45 schema:datePublishedReg 2016-02-01
46 schema:description Treatment of recurrent primary CNS lymphoma (PCNSL) though not standardized most often utilizes whole brain radiotherapy, re-challenge with high-dose methotrexate, or administration of an alkylating chemotherapy. High-dose cytarabine (HD-araC) has been advocated as an active agent in PCNSL but limited information exists regarding single agent activity in the recurrent setting. A retrospective review of 14 patients (10 males, 4 females: median age 60 years) with recurrent PCNSL treated at second recurrence with single agent HD-araC. HD-araC was administered at 3gm/m(2) over a 3-h infusion every 12 h for a total of 4 doses (defined as a cycle of therapy). GM-CSF was administered at conclusion of HD-araC. Patients were clinically and radiographically evaluated every 4-weeks. Common toxicity criteria Grade 3 or 4 toxicity included thrombocytopenia (11 patients; 79%), anemia (10; 71%), fatigue (8; 57%), mucositis (8; 57%), neutropenia (8; 57%) and neutropenic fever (5; 36%). No patient discontinued therapy due to toxicity nor were there any treatment-related deaths. Best response to HD-araC was stable disease in 6 patients (43%), partial response in 5 (36%) and progressive disease in 3 (21%). Median progression free survival 3 months (range 2-5 months; 95% CI 2-4 months) and progression free survival was 0% at 6-months. Median survival after onset of HD-araC was 12 months (range 3-18+ months; 95% CI 3-15 months). Single agent HD-araC has limited activity in recurrent PCNSL and is associated with significant toxicity in this small retrospective study.
47 schema:genre research_article
48 schema:inLanguage en
49 schema:isAccessibleForFree false
50 schema:isPartOf N3748a6b890a74253b9fccdd46fa7aa19
51 Nead7102bfbd445e5abde4f2b11e3595f
52 sg:journal.1094205
53 schema:name High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma
54 schema:pagination 545-550
55 schema:productId N000f8bdc18454610bd01759efdd46838
56 N2997e296c02d4341aef914e87c0cc47f
57 N33cb7bec8177446ba65106ca54c4ee0f
58 N4826d34f602a4413a4af8d2fad99a2eb
59 N90e7edafa0864dc9aa16370d497f8f02
60 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003110938
61 https://doi.org/10.1007/s11060-015-1994-8
62 schema:sdDatePublished 2019-04-10T15:55
63 schema:sdLicense https://scigraph.springernature.com/explorer/license/
64 schema:sdPublisher Na76d82e668144d088392add359b6b067
65 schema:url http://link.springer.com/10.1007%2Fs11060-015-1994-8
66 sgo:license sg:explorer/license/
67 sgo:sdDataset articles
68 rdf:type schema:ScholarlyArticle
69 N000f8bdc18454610bd01759efdd46838 schema:name doi
70 schema:value 10.1007/s11060-015-1994-8
71 rdf:type schema:PropertyValue
72 N0ad20b069bd94de5998505aee7ddf47a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Survival Rate
74 rdf:type schema:DefinedTerm
75 N1cbc259369f040ae9877d9f9ff64da53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Salvage Therapy
77 rdf:type schema:DefinedTerm
78 N1e13ce9369d2435f80fb1ef1ba58ddff schema:name Department of Neurology and Neurological Surgery, Fred Hutchinson Cancer Research Institute, Seattle Cancer Care Alliance, University of Washington, 825 Eastlake Avenue East, POB 19023, Mailstop: G-4940, 98109-1023, Seattle, WA, USA
79 rdf:type schema:Organization
80 N2997e296c02d4341aef914e87c0cc47f schema:name pubmed_id
81 schema:value 26563190
82 rdf:type schema:PropertyValue
83 N327219ba2a5c479badfb5fba207608cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Retrospective Studies
85 rdf:type schema:DefinedTerm
86 N33cb7bec8177446ba65106ca54c4ee0f schema:name readcube_id
87 schema:value 0ed19811fb47587d939f1c6c5980bd6cbe7b69f38a74e31acfa99fee18822a6d
88 rdf:type schema:PropertyValue
89 N3748a6b890a74253b9fccdd46fa7aa19 schema:volumeNumber 126
90 rdf:type schema:PublicationVolume
91 N4826d34f602a4413a4af8d2fad99a2eb schema:name nlm_unique_id
92 schema:value 8309335
93 rdf:type schema:PropertyValue
94 N5176a00f7f2f40458546e9995a6329d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Neoplasm Staging
96 rdf:type schema:DefinedTerm
97 N56352abda9744ea88d19169ec1a9bea8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Cytarabine
99 rdf:type schema:DefinedTerm
100 N6218585c02814b2bb857d0fa7897768c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Female
102 rdf:type schema:DefinedTerm
103 N8bc4bdadd0ba418ab8525a1e922310a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Follow-Up Studies
105 rdf:type schema:DefinedTerm
106 N90e7edafa0864dc9aa16370d497f8f02 schema:name dimensions_id
107 schema:value pub.1003110938
108 rdf:type schema:PropertyValue
109 N9df2b402b3e04fb8b10c5e74b694fd97 rdf:first sg:person.01326261166.36
110 rdf:rest rdf:nil
111 Na76d82e668144d088392add359b6b067 schema:name Springer Nature - SN SciGraph project
112 rdf:type schema:Organization
113 Na7cafcb577de4c3ca733e5d114da020d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Prognosis
115 rdf:type schema:DefinedTerm
116 Nc6fa1d807f574c67a852e29c043b1288 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Central Nervous System Neoplasms
118 rdf:type schema:DefinedTerm
119 Nca716da208764c1080e27edd1e6a26f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Lymphoma, Non-Hodgkin
121 rdf:type schema:DefinedTerm
122 Ne27e6d9004ee4ffb82911317db289285 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Middle Aged
124 rdf:type schema:DefinedTerm
125 Ne5c36423e7704946b4ff879e5ff41c07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Aged
127 rdf:type schema:DefinedTerm
128 Nead7102bfbd445e5abde4f2b11e3595f schema:issueNumber 3
129 rdf:type schema:PublicationIssue
130 Nebed6514c9a644d4b6b99b488e68d116 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Male
132 rdf:type schema:DefinedTerm
133 Necfbf4ab8f154f9ba94e5d1d0a6677bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Humans
135 rdf:type schema:DefinedTerm
136 Ned233d1aa84440cc83ab5de563814e3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Antimetabolites, Antineoplastic
138 rdf:type schema:DefinedTerm
139 Nfebee87f90be48e39a2c3a7e23c73815 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Dose-Response Relationship, Drug
141 rdf:type schema:DefinedTerm
142 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
143 schema:name Medical and Health Sciences
144 rdf:type schema:DefinedTerm
145 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
146 schema:name Oncology and Carcinogenesis
147 rdf:type schema:DefinedTerm
148 sg:journal.1094205 schema:issn 0167-594X
149 1573-7373
150 schema:name Journal of Neuro-Oncology
151 rdf:type schema:Periodical
152 sg:person.01326261166.36 schema:affiliation N1e13ce9369d2435f80fb1ef1ba58ddff
153 schema:familyName Chamberlain
154 schema:givenName Marc C.
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326261166.36
156 rdf:type schema:Person
157 sg:pub.10.1007/pl00022772 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039758880
158 https://doi.org/10.1007/pl00022772
159 rdf:type schema:CreativeWork
160 sg:pub.10.1007/s11060-014-1370-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019739839
161 https://doi.org/10.1007/s11060-014-1370-0
162 rdf:type schema:CreativeWork
163 sg:pub.10.1007/s11060-014-1411-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046834783
164 https://doi.org/10.1007/s11060-014-1411-8
165 rdf:type schema:CreativeWork
166 sg:pub.10.1038/sj.bjc.6603660 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003449325
167 https://doi.org/10.1038/sj.bjc.6603660
168 rdf:type schema:CreativeWork
169 https://app.dimensions.ai/details/publication/pub.1081349247 schema:CreativeWork
170 https://doi.org/10.1002/cncr.26709 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012698413
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1002/cpt1971126944 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051202875
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1016/s0140-6736(09)61416-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031922698
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1016/s1470-2045(10)70229-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034898942
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1093/annonc/mdl070 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041563711
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1093/annonc/mdt385 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039599713
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1093/neuonc/noq011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000678444
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1111/bjh.12938 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005955639
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1158/1078-0432.ccr-11-0625 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005245142
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1182/blood-2013-06-453084 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005748974
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1200/jco.1983.1.9.546 schema:sameAs https://app.dimensions.ai/details/publication/pub.1081839026
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1200/jco.1990.8.7.1277 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078716995
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1200/jco.1992.10.4.635 schema:sameAs https://app.dimensions.ai/details/publication/pub.1076951232
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1200/jco.2001.19.3.742 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074750681
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1200/jco.2005.01.161 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017320169
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1200/jco.2012.46.9957 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041546845
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1200/jco.2013.50.4910 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048451486
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1212/wnl.0000000000000314 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064352101
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1212/wnl.54.8.1707 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064378617
207 rdf:type schema:CreativeWork
 




Preview window. Press ESC to close (or click here)


...